Title:
CYTOKINE STORM INHIBITOR
Document Type and Number:
WIPO Patent Application WO/2016/104436
Kind Code:
A1
Abstract:
The present invention addresses the problem of providing a novel cytokine storm inhibitor. The present invention is a cytokine storm inhibitor that uses HRG as an active ingredient, based on the discovery that HRG acts to inhibit a plurality of types of cytokines. HRG also acts to inhibit inflammatory cytokines and anti-inflammatory cytokines. The present invention is also a drug for preventing or treating systemic inflammatory response syndrome (SIRS), the drug including this cytokine storm inhibitor having HRG as an active ingredient. According to this cytokine storm inhibitor, it is possible to suppress the elevation, in the blood or lung tissue, of levels of two or more cytokines selected from a plurality of types of cytokines, e.g., IL-6, TNF-α, IL-10, KC (CXCL1), MCP-1 (CCL2), MIG (CXCL9), and MIP-1 alpha (CCL3).
Inventors:
NISHIBORI MASAHIRO (JP)
MORI SHUJI (JP)
WAKE HIDENORI (JP)
MORI SHUJI (JP)
WAKE HIDENORI (JP)
Application Number:
PCT/JP2015/085693
Publication Date:
June 30, 2016
Filing Date:
December 21, 2015
Export Citation:
Assignee:
UNIV OKAYAMA NAT UNIV CORP (JP)
International Classes:
A61K38/00; A61P29/00; A61P43/00; C07K14/47
Domestic Patent References:
| WO2013183494A1 | 2013-12-12 |
Foreign References:
| US20120189673A1 | 2012-07-26 |
Other References:
NISHIBORI, M. ET AL.: "Histidine-rich glycoprotein prevents septic lethality through neutrophil regulation", CRITICAL CARE, vol. 18, no. 2, pages 15 - 16
Attorney, Agent or Firm:
SHOJI, Takashi et al. (JP)
Takashi Shoji (JP)
Takashi Shoji (JP)
Download PDF: